Company: ARTL
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001640334-25-002022
Chunk: 0

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 1
Chunk 0
---
ARTELO BIOSCIENCES, INC.

Consolidated Balance Sheets

(Unaudited)

(In thousands, except share data)

   September 30,    December 31,    2025  2024        ASSETS      Current Assets      Cash and cash equivalents $1,720  $2,338 Prepaid expenses and other current assets  107   219 Total Current Assets  1,827   2,557 Operating lease right-of-use assets  73   99 Digital assets  325   - Intangible asset  2,039   2,039 Other assets  3   3 TOTAL ASSETS $4,267  $4,698          LIABILITIES AND STOCKHOLDERS' EQUITY        Current Liabilities        Accounts payable and accrued liabilities $3,868  $1,676 Due to related parties  32   61 Operating lease liabilities - current portion  39   35 Accrued interest - convertible notes  46   - Convertible notes  875   - Total Current Liabilities  4,860   1,772          Operating lease liabilities  40   69 TOTAL LIABILITIES  4,900   1,841          STOCKHOLDERS' EQUITY        Preferred Stock, par value $0.001, 69,444 shares authorized,         0 shares issued and outstanding as of September 30, 2025 and December 31, 2024  -   - Common Stock, par value $0.001, 500,000,000 shares authorized and        1,555,493 and 567,582 shares issued and outstanding as of September 30, 2025, and December 31, 2024, respectively  2   1 Additional paid-in capital  58,491   53,194 Accumulated deficit  (58,849)  (50,136)Accumulated other comprehensive loss   (277)  (202)TOTAL STOCKHOLDERS' (DEFICIT) EQUITY  (633)  2,857          TOTAL LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY $